 |
|
Presenile Dementia in Israel
Therese Treves, MD;
Amos D. Korczyn, MD, MSc;
Nelly Zilber, D es Sc;
Esther Kahana, MD;
Yaffa Leibowitz;
Milton Alter, MD, PhD;
Bruce S. Schoenberg, MD, DrPH
Arch Neurol. 1986;43(1):26-29.
Abstract
| |
• A nationwide epidemiologic study of presenile dementia of the Alzheimer type (PDAT) with onset through age 60 years was carried out in Israel. The Israeli National Neurologic Disease Register and clinical records of all patients discharged from hospitals between 1974 and 1983 with a neurologic or psychiatric diagnosis suggestive of dementia were reviewed. A total of 71 Jewish patients with onset of PDAT between 1974 and 1978 was ascertained. The age at onset in these patients ranged from 43 to 60 years. The median survival was 8.1 years, with slightly longer survival if onset occurred before age 55 years, even after correction for expected mortality according to age and sex. The average annual incidence rate per 100,000 population at risk was 2.4 in the population aged 40 through 60 years. Although the incidence rates were slightly greater for women, the difference between the rates by sex was not statistically significant. The age- and sexadjusted incidence of PDAT per 100,000 population was significantly higher in those born in Europe or America (2.9) than in those born in Africa or Asia (1.4). No significant difference in survival was found between these two groups. The curve of the incidence rates by age for PDAT in Israel is continuous with that for senile dementia of the Alzheimer type collected by similar methods elsewhere, which suggests that one disease process may account for both conditions.
Author Affiliations
From the Departments of Neurology (Drs Treves and Korczyn) and Physiology and Pharmacology (Dr Korczyn), Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel; the Department of Neurology, Tel Aviv Medical Center (Drs Treves and Korczyn); the Neuroepidemiology Unit, Department of Neurology, Hadassah University Hospital, Jerusalem (Drs Zilber and Kahana and Ms Leibowitz); INSERM, Villejuif, France (Dr Zilber); the Department of Neurology, Temple University Medical School, Philadelphia (Dr Alter); and the Neuroepidemiology Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Md (Dr Schoenberg).
Footnotes
Accepted for publication June 24, 1985.
Reprint requests to Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel (Dr Korczyn).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The prevalence of frontotemporal dementia
Ratnavalli et al.
Neurology 2002;58:1615-1621.
ABSTRACT
| FULL TEXT
Long-term survival, place of death, and death certification in clinically diagnosed pre-senile dementia in northern England: Follow-up after 8-12 years
KAY et al.
Br. J. Psychiatry 2000;177:156-162.
ABSTRACT
| FULL TEXT
Seven-Year Survival Rate After Age 85 Years: Relation to Alzheimer Disease and Vascular Dementia
Aevarsson et al.
Arch Neurol 1998;55:1226-1232.
ABSTRACT
| FULL TEXT
Cross-Cultural Research on Alzheimer's Disease: A Critical Review
Smith
Transcultural Psychiatry 1996;33:247-276.
ABSTRACT
Survival in Institutionalized Patients: Influence of Dementia and Loss of Functional Capacities
Hebert et al.
Arch Neurol 1995;52:469-476.
ABSTRACT
Factors Affecting Course and Survival in Alzheimer's Disease: A 9-Year Longitudinal Study
Bracco et al.
Arch Neurol 1994;51:1213-1219.
ABSTRACT
Survival of Outpatients with Alzheimer-type Dementia
Walsh et al.
ANN INTERN MED 1990;113:429-434.
ABSTRACT
Perspectives on the Etiology of Alzheimer's Disease
Mozar et al.
JAMA 1987;257:1503-1507.
ABSTRACT
Functional Disability Associated With Major Neurologic Disorders: Findings From the Copiah County Study
Haerer et al.
Arch Neurol 1986;43:1000-1003.
ABSTRACT
|
